Volume 63, Issue 1, Pages (January 2003)

Slides:

Advertisements

Similar presentations

Renal disease and hypertension in non–insulin-dependent diabetes mellitus Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz Kidney International.

Advertisements

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Volume 58, Issue 6, Pages (December 2000)

Myoung J. Kang, Alistair Ingram, Hao Ly, Kerri Thai, James W. Scholey

Plasma sodium and hypertension

Volume 71, Issue 11, Pages (June 2007)

Furosemide stimulates macula densa cyclooxygenase-2 expression in rats

The Case ∣ Acute renal failure and anemia

A trial of thyroxine in acute renal failure

Membranous nephropathy: When and how to treat

Prenatal exposure to nicotine modifies kidney weight and blood pressure in genetically susceptible rats: A case of gene-environment interaction Zdenka.

Volume 61, Issue 2, (February 2002)

Functional evidence confirmed by histological localization: overlapping expression of erythropoietin and HIF-2α in interstitial fibroblasts of the renal.

Volume 54, Issue 2, Pages (August 1998)

Progression of renal failure and hypertensive nephrosclerosis

Volume 77, Issue 1, Pages 6-8 (January 2010)

Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes Lesley Wassef, Darren J. Kelly, Richard E. Gilbert

Volume 66, Issue 5, Pages (November 2004)

The intrarenal renin-angiotensin system in hypertension

Volume 71, Issue 8, Pages (April 2007)

Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding Kidney International

Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency Fiona E. Mackie, Timothy W. Meyer,

Comorbidity and confounding in end-stage renal disease

Volume 61, Issue 1, Pages (January 2002)

The new role of calcimimetics as vasculotropic agents

Volume 81, Issue 3, Pages (February 2012)

Volume 70, Issue 11, Pages (December 2006)

Tight blood pressure control decreases apoptosis during renal damage

Volume 87, Issue 2, Pages (February 2015)

Impaired response of the denervated kidney to endothelin receptor blockade in normotensive and spontaneously hypertensive rats Radoslav Girchev, Angela.

Volume 75, Issue 2, Pages (January 2009)

Volume 58, Issue 6, Pages (December 2000)

Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: Reversal by lifelong antioxidant supplementation Chang-de Zhan, Ram K. Sindhu, Nosratola.

Volume 70, Issue 12, Pages (December 2006)

Julia E. Tank, Orson W. Moe, William L. Henrich Kidney International

Fructose intake as a risk factor for kidney stone disease

Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen David I. Ortiz-Melo, Robert F. Spurney

Volume 67, Issue 2, Pages (February 2005)

Na+/H+ exchange activity and NHE-3 expression in renal tubules from the spontaneously hypertensive rat Michael S. Lapointe, Chhinder Sodhi, Atul Sahai,

Volume 68, Issue 2, Pages (August 2005)

Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression Klaus Höcherl, Frieder Kees, Bernhard K. Krämer,

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 62, Issue 3, Pages (September 2002)

William J. Welch, Christopher S. Wilcox Kidney International

Neurogenic factors and hypertension in renal disease

Unilateral renal cystic disease

Insulin resistance and hypertension: new insights

Circadian regulation of renal function

Acute phosphate nephropathy

Volume 71, Issue 11, Pages (June 2007)

The treatment of acute interstitial nephritis: More data at last

Volume 57, Issue 2, Pages (October 2000)

The course of the remnant kidney model in mice

Aldosterone in the development and progression of renal injury

Organ transplantation goes to the movies

Volume 62, Issue 4, Pages (October 2002)

Volume 67, Pages S3-S9 (January 2005)

Volume 72, Issue 4, Pages (August 2007)

Is complement a target for therapy in renal disease?

A trial of thyroxine in acute renal failure

Volume 68, Issue 1, Pages (July 2005)

T cells and T-cell receptors in acute renal failure

Non-invasive assessment of kidney oxygenation: a role for BOLD MRI

Structural remodeling of resistance arteries in uremic hypertension

Volume 62, Pages S2-S7 (December 2002)

Quantitative estimation of renal blood flow by power Doppler ultrasonography in renovascular hypertensive dogs Tetsumasa Miyajima, Hiroshi Yokoyama,

Volume 65, Issue 2, Pages (February 2004)

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 63, Issue 1, Pages 202-208 (January 2003) Renal oxygenation defects in the spontaneously hypertensive rat: Role of AT1 receptors William J. Welch, Horst Baumgärtl, Dietrich Lübbers, Christopher S. Wilcox Kidney International Volume 63, Issue 1, Pages 202-208 (January 2003) DOI: 10.1046/j.1523-1755.2003.00729.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Ratio of renal sodium transport to renal oxygen usage in control WKY and hypertensive SHR rats treated for two weeks with vehicle hydrochlorothiazide, hydralazine and reserpine (HHR) or candesartan for two weeks. Values are mean ± SEM. *P < 0.01 compared to WKY given vehicle. Kidney International 2003 63, 202-208DOI: (10.1046/j.1523-1755.2003.00729.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Individual values for renal oxygen usage as a function of tubular sodium transport in SHR kidneys. (A) Compares SHR given vehicle (•; N = 11) with SHR given hydrochlorothiazide, hydralazine and reserpine (HHR; ○; N = 7). The regression for the SHR + vehicle is given by: y = 0.1x + 4.52; r = 0.63; P < 0.01. The regression for SHR given HHR is: y = 0.08x + 4.04; r = 0.742; (P < 0.001). (B) Compares values for SHR given vehicle (•; N = 11) with SHR given candesartan (○; N = 8). The regression for SHR + Cand is: y = 0.05x + 2.89; r = 0.613; P < 0.01. Kidney International 2003 63, 202-208DOI: (10.1046/j.1523-1755.2003.00729.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Partial pressure of oxygen in the SHR kidney. Values are mean ± SEM for the intraluminal recording from the proximal tubule, interstitial recording from the superficial outer cortex and recording from the inner cortex of rats treated for two weeks with vehicle, hydrochlorothiazide, hydralazine and reserpine (HHR) or candesartan. Compared to vehicle treatment, *P < 0.05, **P < 0.01. Kidney International 2003 63, 202-208DOI: (10.1046/j.1523-1755.2003.00729.x) Copyright © 2003 International Society of Nephrology Terms and Conditions